Showing 2581-2590 of 5065 results for "".
DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eEpiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.New SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand mFamily Affair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/family-affair/19697/Fun, fresh, and scientific. That's how host Joel Cohen, MD describes CSF—now in its 11th year. Meeting founder Joel Schlessinger, MD weighs in on his vision for the meeting and what he learned this year.Superficial Radiation for Keloids: SRT-100 in Practice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/superficial-radiation-for-keloids-srt-100-in-practice/19040/Keloids are common. Certain patients, especially patients of color, are more prone to the development of keloids in certain locations, especially areas such as the chest, back, and other areas. Most studies that show that keloids can occur in up to 90 percent of cases when they're excised. The use oDermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral JPrecision Medicine 101
https://practicaldermatology.com/topics/practice-management/precision-medicine-101/20657/DermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years ofBrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-brightguard-covers-nyc-galderma-uncovers-rosacea-burden-dermira-s-qbrexza-approved/18288/BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify the